|Other Names||Arginase-2, mitochondrial, Kidney-type arginase, Non-hepatic arginase, Type II arginase, ARG2|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May play a role in the regulation of extra-urea cycle arginine metabolism and also in down-regulation of nitric oxide synthesis. Extrahepatic arginase functions to regulate L-arginine bioavailability to NO synthase. Since NO synthase is found in the penile corpus cavernosum smooth muscle, the clitoral corpus cavernosum and the vagina, arginase II plays a role in both male and female sexual arousal. It is therefore a potential target for the treatment of male and female sexual arousal disorders.|
|Tissue Location||Expressed most strongly in kidney and prostate, much less strongly in the brain, skeletal muscle, placenta, lung, mammary gland, macrophage, uterus, testis and gut, but apparently not in the liver, heart and pancreas|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Arginase catalyzes the hydrolysis of arginine toornithine and urea. At least two isoforms of mammalian arginaseexists (types I and II) which differ in their tissue distribution,subcellular localization, immunologic crossreactivity andphysiologic function. The type II isoform encoded by this gene, islocated in the mitochondria and expressed in extra-hepatic tissues,especially kidney. The physiologic role of this isoform is poorlyunderstood; it is thought to play a role in nitric oxide andpolyamine metabolism. Transcript variants of the type II generesulting from the use of alternative polyadenylation sites havebeen described.
Warnken, M., et al. Naunyn Schmiedebergs Arch. Pharmacol. 381(4):297-304(2010)Rodrigues Pereira, N., et al. Blood Cells Mol. Dis. 44(3):164-168(2010)Vonk, J.M., et al. Pharmacogenet. Genomics 20(3):179-186(2010)Bjelakovic, L., et al. J Basic Clin Physiol Pharmacol 21(2):187-200(2010)Gannon, P.O., et al. PLoS ONE 5 (8), E12107 (2010) :
If you have any additional inquiries please email technical services at email@example.com.